Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01013597 · ClinicalTrials.gov registry record · Phase 2
Trial of LBH589 in Metastatic Thyroid Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01013597 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 13 participants.
The verdict
NCT01013597, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the tumor response rate in patients with metastatic medullary thyroid cancer (MTC) or radioiodine resistant differentiated thyroid cancer (DTC) after receiving treatment with LBH589 20 mg by mouth, three times weekly. Time to progression, overall survival, toxicity, tolerability, and Notch1 protein expression patterns will also be evaluated.
Interventions
- DRUG LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-01 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01013597
The ClinicalTrials.gov registry entry for NCT01013597 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LBH589 is the first listed.
NCT01013597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01013597 about?
NCT01013597 is a clinical study titled "Trial of LBH589 in Metastatic Thyroid Cancer". The purpose of this study is to evaluate the tumor response rate in patients with metastatic medullary thyroid cancer (MTC) or radioiodine resistant differentiated thyroid cancer (DTC) after receiving treatment with LBH589 20 mg by mouth, three times weekly. Time to progression, overall survival, to...
What is the current status of trial NCT01013597?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2010-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01013597?
The interventions under investigation include: LBH589 (DRUG).
Who is sponsoring clinical trial NCT01013597?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.